Harrow, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Harrow, Inc. (HROW) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$62.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2022-03-10
- Harrow, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$8.00K.
- Harrow, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$15.00K.
- Harrow, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$23.00K, a 154.76% decline year-over-year.
- Harrow, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$16.00K, a 164.00% decline year-over-year.
- Harrow, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2020 was -$62.00K.
- Harrow, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2019 was -$293.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 12 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$23.00K derived: sum of 2 quarters · filed 2022-03-10 | -$46.00K derived: sum of 3 quarters · filed 2022-03-10 | -$62.00K 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | -$15.00K 10-Q · filed 2021-11-09 | -$38.00K derived: sum of 2 quarters · filed 2021-11-09 | -$54.00K 10-Q · filed 2021-11-09 | -$119.00K derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | -$23.00K 10-Q · filed 2021-08-10 | $23.00K 10-Q · filed 2020-08-10 | -$39.00K 10-Q · filed 2021-08-10 | $39.00K 10-Q · filed 2020-08-10 | -$104.00K derived: sum of 3 quarters · filed 2021-08-10 | -$265.00K derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | -$16.00K 10-Q · filed 2021-05-11 | $16.00K 10-Q · filed 2020-05-11 | -$81.00K derived: sum of 2 quarters · filed 2021-05-11 | -$242.00K derived: sum of 3 quarters · filed 2021-05-11 | -$200.00K derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | -$65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | -$226.00K derived: sum of 2 quarters · filed 2021-03-08 | -$184.00K derived: sum of 3 quarters · filed 2021-03-08 | -$293.00K 10-K · filed 2021-03-08 | $293.00K 10-K · filed 2020-03-13 | |||
| 2019-09-30 | -$161.00K 10-Q · filed 2020-11-09 | $161.00K 10-Q · filed 2019-11-13 | -$119.00K derived: sum of 2 quarters · filed 2020-11-09 | -$228.00K 10-Q · filed 2020-11-09 | $228.00K 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $42.00K 10-Q · filed 2020-08-10 | $67.00K 10-Q · filed 2020-08-10 | ||||||
| 2019-03-31 | $25.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |